The positive cases of coronavirus disease-2019 (COVID-19) in Indonesia has been increasing rapidly since the first case found in March 2020 to date. Coronavirus 2 (SARS-CoV-2) virus disrupts human normal immune system resulting in uncontrolled inflammatory response. Based on our research and experience in doing cell therapy for 9 years, activated platelet-rich plasma (PRP) produces anti-inflammatory effects in inflammatory condition that is beneficial for tissue regeneration. In this study, we aimed to evaluate the potential of autologous activated platelet-rich plasma (aaPRP) and the outcomes for treating severe Coronavirus Disease-2019 (COVID-19) patients in Intensive Care Unit (ICU).
PRP decreases IL-1β, IL-6, IL-8, and TNFα inflammatory genes expression while also reduces
IL-1β and TNFα inflammatory cytokines production. PRP has also been showed to contain
interleukin 1 receptor antagonist (IL-1RA), an anti-inflammatory cytokines that suppress IL-6
secretion.
Combination Product: autologous activated platelet-rich plasma
Patient received standard medication for COVID-19 management and autologous activated platelet-rich plasma on day 1, 3 and 5 while patient in ICU. On day 0, 4 and 6, hematology analysis, multicytokines measurement and thorax X-ray were done to each patient
Drug: Avigan
Patient received avigan 2x1,600 mg for a day, followed by 2x600 mg for five consecutive days.
Inclusion Criteria:
- severe covid-19 patient in ICU
Exclusion Criteria:
- CKD on hemodialysis, HIV positive, hepatitis, pregnant, destroyed lung, cancer
Koja Regional Public Hospital
Jakarta, DKI Jakarta, Indonesia
Investigator: Louis Martin Christoffel, MD
Contact: 6281340062037
louischristoffel200@gmail.com
Karina Karina, MD, PhD
62.21.3909333
karina@hayandra.com
Imam Rosadi, M.Sc
6285719593848
imam.rosadi@hayandra.com
Louis Martin Christoffel, MD, Principal Investigator
Koja Regional Public Hospital